ENZ Related StreetInsider.com Reports
-
Enzo Biochem, Inc. (ENZ) Reports Q3 Loss of $0.15/Share
-
Enzo Biochem, Inc. (ENZ) Posts Weaker Q2 Results
-
Enzo Biochem, Inc. (ENZ) Narrows Q1 Loss to 9c/Share
-
Trading Radar for 12/11: Dollar General (DG), L & L Energn (LLEN), The Pantry (PTRY), Hanwha SolarOne (HSOL) Report
-
Enzo Biochem (ENZ) Makes EarlyCDT-Lung by Enzo Clinical Labs Available
-
Unusual 11 Mid-Day Movers 11/05: (ICAD) (NTE) (BMRN) Higher; (EBIX) (RDN) (PCYC) Lower
-
Enzo Biochem (ENZ) trading halted with news pending
-
Enzo Biochem, Inc. (ENZ) Widens Q4 Loss to 69c/Share
-
Unusual 11 Mid-Day Movers 06/20: (GEVO) (ENZ) (VVTV) Higher; (FSII) (CYTK) (ETH) Lower
-
Morning Movers 06/20: (GEVO) (VVTV) (MITK) Higher; (FSII) (LZB) (GAGA) Lower
-
Enzo Biochem, Inc. (ENZ) Reports Q3 Loss of $0.09/Share
-
Enzo Biochem Inc. (ENZ) Expands Business Agreement with Cosmo Bio Co.
-
Enzo Biochem, Inc. (ENZ) Reports Q2 Loss of $0.04
-
Enzo Biochem (ENZ) Gets NY DoH Approval for ColonSentry Test
-
Enzo Biochem, Inc. (ENZ) Misses Q1 Views
-
Enzo Biochem (ENZ) Unit Updates on Sulfated Tyrosine
-
Enzo Biochem (ENZ) Unit Acquires Biomarker Quantification Test
-
Enzo Biochem (ENZ) Posts Narrower than Expected Q3 Loss
-
Enzo Biochem (ENZ) Reports Q2 Loss of 15c
-
Enzo Biochem (ENZ) Posts Q4 Adj-Loss of 10c
-
Enzo Biochem (ENZ) Commences Optiquel Clinical
-
Enzo Biochem (ENZ) Gives Details on Plan to Streamline Operations; Sees $500K Charge for Severance, Sees Positive Operating Cash Flow in '11
-
Enzo Biochem (ENZ) Receives Approval to Conduct Business in Pennsylvania
-
Enzo Biochem (ENZ) Files $50M Mixed Shelf
-
Enzo Biochem (ENZ) Reports Q3 Loss of $0.12, Misses by 4c
-
Enzo Biochem (ENZ) Announces Agreement to Market MultiGEN's Diagnostic Tests In New York
-
Enzo Biochem (ENZ) Announces Agreement to Market MultiGEN's DNA Sequencing Diagnostic Test in New York
-
Enzo Biochem (ENZ) Receives Favorable Ruling in Patent Suit; Shares Jump
-
Enzo Biochem (ENZ) Receives Favorable Judgment by US Patent Office Related to Application for Nucleic Acid Signal Amplification
-
Enzo Biochem (ENZ) Posts Q1 Loss of $0.05, Beats by 5c
-
Enzo Biochem (ENZ) Reports Q4 Loss of $0.14, Misses by 6c
-
Rodman & Renshaw Initiates Coverage of Enzo Biochem (ENZ) with a Market Outperform
-
Enzo Biochem (ENZ) Reports Q3 Loss of $0.11
-
Notable Mergers and Acquisitions of the Day 3/13: APP, ENZ, GRS
-
Enzo Biochem (ENZ) Buys Assay Designs For $12.2 Million
-
Enzo Biochem (ENZ) Reports a Q2 Loss on Record Revenues
-
Enzo Biochem (ENZ) Issues Operational, Financial Update at Annual Meeting
-
Enzo Biochem (ENZ) Reports Q4 Loss of $0.09
-
Enzo Biochem (ENZ) Misses Q3 EPS by 1c
-
Enzo Biochem (ENZ) Acquires BIOMOL International; Accretive to Earnings
-
Enzo Biochem (ENZ) Reports Strong Q1 Earnings
-
StreetInsider.com After-Hours Movers 10/15
-
Lazard Capital Starts Enzo Biochem (ENZ) at Buy
-
Enzo Biochem (ENZ) Acquires Axxora Life Sciences for $16.3 Million
-
Enzo Biochem (ENZ) Enters Cross-Licensing Agreements with Abbott
-
U.S. Patent Board Awards Enzo Biochem (ENZ) Judgment in Patent Interference after Princeton University Concedes Priority
-
Enzo Biochem (ENZ) Says Federal Court Issues Favorable Ruling Upholding Key Patent Claim Terms
-
Enzo Biochem (ENZ) Receives License to Comprehensive Non-PCR Based Amplification Technology
-
Enzo Biochem (ENZ) Subsidiary Selected as Regional Provider of Medical Laboratory Services for UnitedHealthcare (UNH)
-
Sigma-Aldrich (SIAL) Reaches Settlement with Enzo Biochem (ENZ)
Back to ENZ Stock Lookup
